Resources

Researchers have discovered a drug target that could potentially help tackle drug-resistant tuberculosis, one of the biggest causes of death worldwide.

The Modelling-Informed Medicine Centre (MiMeC) will provide a new UK hub for research in the emerging modelling-informed medicine field.

The launch of the NIHR Industry hub last week, the launch of UKRI/Innovate strategy this Thursday and a landmark Mansion House event tomorrow all signal forward momentum on Industrial Strategy.

In this guest blog, Valerie Pinkerton, UK TNFD & Transition Plans Lead at the Green Finance Institute, explores why nature-related risks are becoming increasingly important for the pharmaceutical and biotechnology sector.

BIA member Asma Aslam, Senior Corporate Tax Manager at Frazier & Deeter, explores how a period of tighter capital and greater scrutiny has reshaped expectations around execution, value creation and operational discipline.

PIR International recently partnered with Gilgamesh Pharmaceuticals in appointing Bridget Walton as VP Regulatory Affairs.

The BioIndustry Association (BIA) is pleased to announce the appointment of Will James, partner at Osborne Clarke LLP, as Vice-Chair of its Intellectual Property Advisory Committee (IPAC).

Nominations were declared open today for the Life Sciences Week Awards - the climax of a national programme of health tech events launched in Birmingham, UK.

Quell announced last week that it has initiated the CHILL Phase 1/2 clinical study evaluating its QEL-005 CAR-Treg therapy in patients with Refractory Rheumatoid Arthritis and Systemic Sclerosis. Advancement of the program into clinical development follows the recent approval by UK MHRA of the company’s Clinical Trial Application (CTA). The CHILL clinical trial is a multinational basket study that will recruit participants in the UK, Germany and Spain. The trial is actively recruiting in the UK and early data are expected during Q1'27.

Free-to-attend conference takes place at AstraZeneca in Gothenburg, Sweden from 6-7 May

Poolbeg Pharma announces the appointment of Dr Adrian Kilcoyne to its Scientific Advisory Board.

Coulter Partners is pleased to announce the placement of David Rosenbaum, Ph.D. as Chief Development Officer (CDO).

Brainomix 360 Stroke has been deployed in all 25 sites, marking the first time the entire WVU network has access to a unified AI solution to support faster and more consistent acute stroke decision-making.

C‑Further launches its first targeted paediatric cancer programmes, collaborating with global academic and industry partners to advance new therapeutics.

Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, today announced that it has established a US subsidiary at The Engine in Cambridge, MA.

EnteroBiotix has completed enrolment in the Phase 2a MAST trial of EBX-102-02, investigating intestinal microbiota transplant prior to allogeneic stem cell transplantation in patients with haematological malignancies.

Glasgow’s newest purpose-built life sciences laboratory facility, the Health Innovation Hub (HiH), was officially opened by Wes Streeting, Secretary of State for Health and Social Care.

In this week’s update, we explore the growing momentum of the Health Data Research Service (HDRS), celebrate the resilience of our community following the "Big WiB" Women in Biotech event, and analyse the sector's outlook following the Chancellor's Spring Statement.

SignaCor Therapeutics has been named the winner of Discovery Park's startup growth programme for innovations in cardiovascular health, securing £250k in funding from venture capital firm Zinc.